Genfit: leader of SBF 120 after positive data
(CercleFinance.com) - The Genfit share is steaming ahead on the SBF 120 on Monday, up over 9% after a peak of +12% at lunchtime, after the group announced positive data regarding a diagnostic tool.
At the 2017 AASLD Liver Meeting in Boston, on Sunday Genfit presented encouraging results for NIS4, a non-invasive blood tool developed for the diagnosis of non-alcoholic steatohepatitis (NASH).
The French biopharmaceutical company announced that its tool has performed better than other non-invasive tools in the diagnosis of NASH in patients suffering from type 2 diabetes. The program relies on the internal discovery of an algorithm with 4 variables that can potentially replace the biopsy with a single blood test. The study shows that patients with type 2 diabetes have an increased risk of developing NASH.
Copyright (c) 2019 CercleFinance.com. All rights reserved.